A Study of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant Women

Condition:   Healthy Interventions:   Biological: Ad26.ZEBOV;   Biological: MVA-BN-Filo Sponsors:   Janssen Vaccines & Prevention B.V.;   Center for Family Health Research (CFHR);   Coalition for Epidemic Preparedness Innovations (CEPI);   Emory University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

AbstractPurpose of ReviewAs research efforts have advanced to understand the pathophysiology of viral hemorrhagic fevers (VHF) and other epidemic viral infections and develop medical countermeasures such as vaccines, pregnant women have remained an underexamined subgroup. To better understand the implications of future outbreaks of VHF for pregnant women amidst an evolving vaccine landscape, we examine three pathogens —yellow fever, Ebola, and Lassa fever—each with different levels of evidence and understanding of disease in pregnancy and at varying stages of vaccine development.Recent FindingsThere are very li...
Source: Current Tropical Medicine Reports - Category: Tropical Medicine Source Type: research
AbstractPurpose of ReviewEbola virus infection has one of the highest overall case fatality rates of any viral disease. It has historically had an especially high case mortality rate among pregnant women and infants —greater than 90% for pregnant women in some outbreaks and close to 100 % in fetuses and newborns. The Merck recombinant vaccine against Ebola virus, termed rVSV-ZEBOV, underwent clinical trials during the 2013–2015 West Africa Ebola epidemic where it was found to be 100% efficacious. It was sub sequently used during the 2018 DRC Équateur outbreak and in the 2018 DRC Kivu Ebola which is still...
Source: Current Tropical Medicine Reports - Category: Tropical Medicine Source Type: research
More than 1,500 deaths and 2,500 people sickened – that’s the recent account of the ebola outbreak in the Democratic Republic of Congo (DRC) raging in the country since last August, and recently declared a public health emergency of international concern. Experts say efforts to contain the virus are hindered by biological, public health, political, and cultural issues, but we looked around what digital health technologies could do to mitigate the spread and the devastation of the infectious disease. The Spaghetti-like virus… The lethal Ebola virus first appeared in 1976 around a river in Congo &nda...
Source: The Medical Futurist - Category: Information Technology Authors: Tags: Future of Medicine Africa AI artificial intelligence Congo digital digital health digital maps disease disease outbreak ebola epidemic Innovation technology Source Type: blogs
Pregnant women &vaccines against emerging epidemic threats: Ethics guidance for preparedness, research, and response. Vaccine. 2019 May 03;: Authors: Krubiner CB, Faden RR, Karron RA, Little MO, Lyerly AD, Abramson JS, Beigi RH, Cravioto AR, Durbin AP, Gellin BG, Gupta SB, Kaslow DC, Kochhar S, Luna F, Saenz C, Sheffield JS, Tindana PO, PREVENT Working Group Abstract Zika virus, influenza, and Ebola have called attention to the ways in which infectious disease outbreaks can severely - and at times uniquely - affect the health interests of pregnant women and their offspring. These examples also hig...
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research
In this study, we evaluated ATA as a potential antiviral drug against ZIKV replication. The antiviral activity of ATA against ZIKV replication in vitro showed median inhibitory concentrations (IC50) of 13.87 ± 1.09 μM and 33.33 ± 1.13 μM in Vero and A549 cells, respectively; without showing any cytotoxic effect in both cell lines (median cytotoxic concentration (CC50)> 1,000 μM). Moreover, ATA protected both cell types from ZIKV-induced cytopathic effect (CPE) and apoptosis in a time- and concentration-dependent manner. In addition, pre-treatment of Vero cells with ATA for up to 72 h also resulted...
Source: Frontiers in Microbiology - Category: Microbiology Source Type: research
Conclusion
Source: blog.bioethics.net - Category: Medical Ethics Authors: Tags: Health Care syndicated Source Type: blogs
Source: Wellcome Trust. Published: 9/2018. This 96-page guidance provides a roadmap for the ethically responsible, socially just, and respectful inclusion of the interests of pregnant women in the development and deployment of vaccines against emerging pathogens. It discusses how recent epidemics, including Zika virus, Lassa Fever, Ebola, and H1N1 influenza, have highlighted the ways in which infectious disease outbreaks can severely affect the health interests of pregnant women and their offspring. It specifies 22 concrete recommendations, organized around three key areas: public health preparedness, R&D, and vaccine delivery. (PDF)
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - Category: International Medicine & Public Health Source Type: news
Source: Center for Global Development (CGD). Published: 10/29/2018. In this one-hour, 22-minute panel discussion, speakers recount their experiences on the ground in Sierra Leone during the height of the 2014-2015 Ebola epidemic. They examine the policy and operational lessons learned that emerged from that effort; and reflect on the development and delivery of an efficacious Ebola vaccine, and how current approaches can perpetuate the exclusion of a group desperately in need of protection: pregnant women. (Video or Multimedia)
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - Category: International Medicine & Public Health Source Type: news
More News: Ebola | Ebola Vaccine | Epidemics | Epidemiology | Pregnancy | Research | Study | Vaccines | Women